Bone defects resulting from trauma, infection, tumors or inherent genetic disorders pose a significant burden on healthcare systems. Bone regeneration requires the use of grafting materials such as bone autografts, which are currently considered the gold standard treatment. Nevertheless, their low availability and the associated donor site morbidity limit autografts use, leading to a growing clinical need for the development of novel bone grafts that will effectively substitute and augment the bone. The technology is a novel graft using porcine bone extracellular matrix (pbECM), thus harnessing the natural osteoconductive and osteoinductive properties of the bone to regenerate the tissue, while eliminating the immunogenic risk of its porcine origin. To guarantee perfect structural compatibility between the graft and any complex cavity in the treated bone, the pbECM is processed into a thermally-induced hydrogel that can be applied as a liquid directly into the defect site and gel at body temperature. The use of such hydrogel that can be administered in a minimally invasive manner will also reduce the operative risk involved in invasive implantation surgery, and allow the local delivery of osteoinductive factors through a complementary delivery system.
- Actively promote bone regeneration through the mechanical and biological support of the pcECM and the controlled local release of osteoinductive factors
- Standardized and robust production
- Lower costs
- Higher availability
- Eliminated immunogenicity while preserving its biological function
Applications and Opportunities
- Bone regeneration